Recently, a pre-specified analysis from the ODISSEY Outcomes trial, which randomized 18,924 post-ACS patients on high-intensity statin treatment relative to alirocumab vs. placebo, found that baseline Lp(a) levels were linearly associated with MACE (composite of coronary death, MI, stroke, or unstable angina), fatal and non-fatal MI, and cardiovascular death, independently of baseline LDL values. Here, LPA is linked to myocardial infarction.